ASCO Highlights In Brief
Amgen's Prolia: Data presented at the American Society of Clinical Oncology meeting in Chicago included new information on the use of Amgen's RANK ligand inhibitor, Prolia (denosumab), in delaying skeletal related events in prostate cancer patients with bone metastases. The study met its primary and secondary endpoints showing superiority in a head-to-head trial against Novartis' Zometa (zoledronic acid) in postponing time to the first SRE by 20.7 months compared to 17.1 months. Overall, the data were inline with the expectations of analysts, who remain bullish on the compound in the wake of its approval in the post-menopausal osteoporosis setting and Amgen's decision to price the compound aggressively (1"The Pink Sheet," June 7, 2010). The study was typical of Amgen's showing at the June 4-7 cancer meeting, which was generally positive but incremental
You may also be interested in...
Amgen's first-in-class Prolia (denosumab) is burdened with a high price point as it joins the competitive and price-sensitive osteoporosis market. With a wholesale acquisition cost of $1,650 a year - including two $825 injections - Prolia will officially cost more than the leading branded drugs Actonel (risedronate), Boniva (ibandronate) and Reclast (zoledronic acid), and it will have to compete against generic versions of the gold standard, alendronate (Merck's Fosamax)
Bristol's acquisition offer of $16 per share is certainly generous, but Medarex has a lengthy and promising pipeline to offer and one which would have needed deep pockets down the road.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011